Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine

2.1 Cabozantinib (Cabometyx, Ipsen) is indicated 'as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy'.

2.2 The dosage schedule is available in the summary of product characteristics for cabozantinib.

2.3 The list price of cabozantinib is £5,143 for a 30‑tablet pack of 20 mg, 40 mg or 60 mg tablets (excluding VAT; BNF online accessed March 2023).

2.4 The company has a commercial arrangement. This makes cabozantinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.